



Liquidia Technologies to Present at Jefferies London Healthcare Conference

November 9, 2018

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- [Liquidia Technologies, Inc. \(Nasdaq:LQDA\)](#) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its [proprietary PRINT® technology](#) to transform the lives of patients, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the Jefferies London Healthcare Conference on Thursday, November 15, 2018 at 12:40 p.m. GMT (7:40 a.m. ET).

A link to the live audio webcast and replay of the presentation will be available on the [Events & Presentations](#) page of the company's corporate website, and will be archived for a minimum of 90 days.

About Liquidia Technologies

[Liquidia Technologies](#) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its [proprietary PRINT® technology](#) to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT® particle engineering platform: [LIQ861](#) for the treatment of pulmonary arterial hypertension and [LIQ865](#) for the treatment of local post-operative pain. Being evaluated in a Phase 3 clinical trial (INSPIRE), LIQ861 is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia's PRINT® technology. For more information visit our website at www.liquidia.com.

Contact:

Jennifer Almond
Director, Investor Relations & Corporate Communications
919.328.4389
IR@liquidia.com



Source: Liquidia Technologies, Inc.